Johnson & Johnson (J&J; NYSE: JNJ) has announced that a Phase III trial for its dual-acting biologic Tremfya (guselkumab) has successfully met its composite co-primary endpoints in patients with moderately to severely active Crohn’s disease (CD) when compared to placebo. The study also demonstrated that the IL-23-focused subcutaneous maintenance therapy showed superior results to J&J’s own IL-12/23 blocker Stelara (ustekinumab) in terms of clinical remission and four endoscopic endpoints.
The safety profile of Tremfya was found to be consistent with that of its currently approved indications, with a low proportion of serious adverse events reported.
As stated in the press release, Tremfya is currently under review for the treatment of moderately to severely active ulcerative colitis (UC) and moderately to severely active CD.- Flcube.com
